| Citation: |
ZHUANG Yan, HUANG Hao, ZHOU Junyi, PAN Ting, DING Xiaorong, YUAN Ying, ZHONG Xiaomin. MDM2 Inhibitor RG-7388 Promotes Apoptosis and Cell Cycle Arrest of Diffuse Large B Cell Lymphoma[J]. Cancer Research on Prevention and Treatment, 2023, 50(3): 243-248. DOI: 10.3971/j.issn.1000-8578.2023.22.0873
|
To investigate the effect of MDM2 inhibitor RG-7388 on the proliferation, cell cycle, and apoptosis of diffuse large B-lymphoma (DLBCL) cells.
DLBCL cell strains SUDHL2 and HBL1 were treated with 2, 4, and 8 μmol/LRG7388, respectively. Cell proliferation was detected by CCK8 and EdU methods. Apoptosis was measured by Annexin V–FITC/PI double staining and Caspase 3/7-Glo enzyme activity methods. Cell cycle was assessed by flow cytometry. Changes in the expression of cell cycle and apoptosis-related proteins were determined by Western blot.
The IC50 of RG7388 for inhibiting SUDHL2 and HBL1 cells were 3.36 and 3.76 μmol/L, respectively, and the inhibitory effect of RG7388 was dose dependent. The proportions of G1 phase and apoptotic cells in the SUDHL2 and HBL1 cells treated with different doses of RG7388 were significantly higher than those in the control group (all P<0.05). The activity of Caspase 3/7 increased gradually with RG7388 concentration, compared with that in the control group. The expression levels of p53, p27, p21, and PARP increased, whereas the expression of Mcl-1 and Bcl-xL was down-regulated (all P<0.05).
MDM2 inhibitor RG-7388 inhibits the proliferation of DLBCL cells, triggers cell cycle arrest in the G1 phase, and induces apoptosis through the p53 pathway.
Competing interests: The authors declare that they have no competing interests.
| [1] |
陈丽玲, 崔东亚, 蔡少丽. 弥漫大B细胞淋巴瘤中CD30的表达及其作用的研究进展[J]. 中国细胞生物学学报, 2021, 43(12): 2490-2496.
Chen LL, Cui DY, Cai SL. The Expression and Role of CD30 in Diffuse Large B-cell Lymphoma[J]. Zhongguo Xi Bao Sheng Wu Xue Xue Bao, 2021, 43(12): 2490-2496.
|
| [2] |
Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study[J]. Lancet, 2020, 396(10254): 839-852. doi: 10.1016/S0140-6736(20)31366-0
|
| [3] |
王芳, 邓体瑛. 双微体2蛋白抑制药Idasanutlin概述[J]. 中国药师, 2018, 21(9): 1645-1647. doi: 10.3969/j.issn.1008-049X.2018.09.037
Wang F, Deng TY. Summary on Idasanutlin as an MDM2 Inhibitor[J]. Zhongguo Yao Shi, 2018, 21(9): 1645-1647. doi: 10.3969/j.issn.1008-049X.2018.09.037
|
| [4] |
Natarajan U, Venkatesan T, DhandayuthapaniS, et al. Differential mechanisms involved in RG-7388 and Nutlin-3 induced cell death in SJSA-1 osteosarcoma cells[J]. Cell Signal, 2020, 75: 109742. doi: 10.1016/j.cellsig.2020.109742
|
| [5] |
Khurana A, Shafer DA. MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388)[J]. Onco Targets Ther, 2019, 12: 2903-2910. doi: 10.2147/OTT.S172315
|
| [6] |
Vernooij L, Bate-Eya LT, Alles LK, et al. High-Throughput Screening Identifies Idasanutlin as a Resensitizing Drug for Venetoclax-Resistant Neuroblastoma Cells[J]. Mol Cancer Ther, 2021, 20(6): 1161-1172. doi: 10.1158/1535-7163.MCT-20-0666
|
| [7] |
Teras LR, DeSantis CE, Cerhan JR, et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes[J]. CA Cancer J Clin, 2016, 66(6): 443-459. doi: 10.3322/caac.21357
|
| [8] |
Sawalha Y. Relapsed/refractory diffuse large B-cell lymphoma: A look at the approved and emerging therapies[J]. J Pers Med, 2021, 11(12): 1345. doi: 10.3390/jpm11121345
|
| [9] |
Konopleva M, Martinelli G, Daver N, et al. MDM2 inhibition: an important step forward in cancer therapy[J]. Leukemia, 2020, 34(11): 2858-2874. doi: 10.1038/s41375-020-0949-z
|
| [10] |
Chamberlain V, Drew Y, Lunec J. Tipping Growth Inhibition into Apoptosis by Combining Treatment with MDM2 and WIP1 Inhibitors in p53WT Uterine Leiomyosarcoma[J]. Cancers (Basel), 2021, 14(1): 14. doi: 10.3390/cancers14010014
|
| [11] |
Italiano A, Miller WH, Blay Jean-Yves, et al. PhaseⅠ study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors[J]. Invest New Drugs, 2021, 39(6): 1587-1597. doi: 10.1007/s10637-021-01141-2
|
| [12] |
Fang Y, Liao GC, Yu B. Small-molecule MDM2/X inhibitors and PROTAC degraders for cancer therapy: advances and perspectives[J]. Acta Pharm Sin B, 2020, 10(7): 1253-1278. doi: 10.1016/j.apsb.2020.01.003
|
Figures(5) / Tables(1)
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: